CRO Advisors LLC Founder Stephen J. Sullivan Joins PHT Corporation Board of Directors

  CRO Advisors LLC Founder Stephen J. Sullivan Joins PHT Corporation Board of
  Directors

Former executive from CROs including Harlan Laboratories and Covance brings
industry knowledge to PHT BOD

Business Wire

BOSTON & GENEVA -- October 8, 2013

PHT Corporation announced that pharmaceutical, diagnostic and biotechnology
senior executive Stephen J. Sullivan joined its Board of Directors. PHT is the
leading provider of innovative technology systems used to collect
patient-driven eData for clinical research.

Stephen J. Sullivan, Founder of CRO Advisors and member of the PHT Corporation
Board of Directors (P ...

Stephen J. Sullivan, Founder of CRO Advisors and member of the PHT Corporation
Board of Directors (Photo: Business Wire)

PHT President, CEO and Director Philip Lee said, “It is a pleasure to welcome
Steve Sullivan to the PHT Board of Directors. Steve is a proven leader in
guiding and advising public, private and venture-backed companies in the
clinical trial services market sector. His unique knowledge of the industry
and experience growing successful companies is invaluable to PHT as the
company enters a new stage of rapid growth.”

Mr. Sullivan is Founder of CRO Advisors LLC, a consulting practice that
advises CRO leaders, partners and investors to make and implement strategic
decisions. Previously Mr. Sullivan was President, CEO and Director of Harlan
Laboratories, a pre-clinical CRO and Research Models and Services Company.
Prior to Harlan, Mr. Sullivan was a Senior Vice President at Covance, and
President of the Central Labs Group and Clinical Support Services. Earlier,
Mr. Sullivan held management positions at Xenometrix; Abbott Laboratories;
Dart & Kraft, Inc.; Baxter International; C. R. Bard, Inc.; and, Johnson &
Johnson.

PHT is the leader in capturing patient experience data in clinical trials and
there is increased demand from CROs and trial sponsors for these services. Mr.
Sullivan said, “I am delighted to join this talented team of executives and
board members who are committed to build upon PHT’s leadership position in
ePRO.”

Mr. Sullivan is non-executive Chairman of the Boards of Molecular Imaging
Research, Inc. and BioreclamationIVT, Inc. and is on the board of PDI, Inc.

Mr. Sullivan received his MBA from Rutgers University and BS from the
University of Dayton. He has been an Adjunct Professor at J.L. Kellogg
Graduate School. Mr. Sullivan was a U.S. Marine Corps officer and Vietnam
veteran.

About PHT Corporation

PHT Corporation helps pharmaceutical companies and CROs conduct clinical trial
programs with greater confidence, ease and accuracy. Proven PHT electronic
clinical outcome assessment (eCOA) Systems collect patient-driven eData via
smartphones, tablets and the web. This data, available via StudyWorks™ online
reporting portal, provides sponsors and clinicians with a real time window
into how patients feel and function. PHT has helped trial sponsors collect
patient-driven eData in 650+ global trials resulting in 16+ regulatory
approvals. PHT Clinical Science and Consulting offers the scientific,
regulatory, and technological expertise today’s eCOA market demands and
patients deserve. Visit www.phtcorp.com for more information on PHT. Follow
PHT on LinkedIn, Twitter, Google+ and YouTube.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20131008005163/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50723000&lang=en

Contact:

For PHT Corporation
Brenda Nashawaty, 617-688-3253
brenda@nashawaty.com
 
Press spacebar to pause and continue. Press esc to stop.